BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 28447301)

  • 41. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
    Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
    Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
    Rizk AN; Hesketh PJ
    Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
    Herrstedt J; Roila F; Warr D; Celio L; Navari RM; Hesketh PJ; Chan A; Aapro MS
    Support Care Cancer; 2017 Jan; 25(1):277-288. PubMed ID: 27443154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
    Clark-Snow RA; Vidall C; Börjeson S; Jahn P
    Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP; Madelaine I; Scotté F
    Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.
    Dupuis LL; Nathan PC
    Paediatr Drugs; 2010; 12(1):51-61. PubMed ID: 20034341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
    Oo TH; Hesketh PJ
    Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Getting it right the first time: recent progress in optimizing antiemetic usage.
    Schwartzberg L
    Support Care Cancer; 2018 Mar; 26(Suppl 1):19-27. PubMed ID: 29556812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
    Vig S; Seibert L; Green MR
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
    Navari RM; Aapro M
    N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
    Navari RM
    Drugs; 2009; 69(5):515-33. PubMed ID: 19368415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
    Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.